Prevail Partners

What Prevail Partners does

Prevail Partners, LLC is a privately-held life sciences investment fund headquartered in Philadelphia, Pennsylvania, founded in 2008. The firm invests equity capital into companies sponsoring Phase I through Phase IV clinical trials in therapeutics, devices, and diagnostics, screening a universe of 50-60 vetted prospects and selecting investments that demonstrate potential for significant value inflection through clinical success.

The fund's core technology and differentiator is delivered through its wholly-owned affiliate Prevail InfoWorks, Inc. (established 2007), which provides patented benchmarking libraries and an analytics platform used to compare trial metrics against historical norms, identify risk reduction opportunities, and project cost and timelines. Additional proprietary tools include Projected Outcome Analysis (POA), a real-time patient-by-patient analytics capability, a patented collaboration platform enabling ongoing strategic partner (licensee, investor, payer) input during trials, and a guaranteed 48-hour database lock. The Build-to-Suit Program offers project financing and turnkey clinical/non-clinical infrastructure, transforming clinical development from a fixed to a variable cost via a separate spin-company vehicle.

Prevail Partners monetizes through equity returns and capital gains realized on successful clinical milestones and exits (licensing or commercialization), rather than disclosed management fees. Its go-to-market is direct enterprise origination via proprietary deal sourcing, deep industry contacts cultivated by President Mary Schaheen (over 3,000 C-level relationships), and an investment committee vetting process. Advisory board access to former senior FDA officials, including former FDA Commissioner Dr. Lester Crawford, supports regulatory risk de-risking. A documented case history is the pivotal Phase III Tyvaso trial run through United Therapeutics' subsidiary LungRx, and a 2025 strategic partnership with Omnix Medical supports Phase 2 development of OMN6 for resistant bacterial infections.

Name

Prevail Partners

Legal name

Prevail Partners, LLC

Website

https://prevailpartners.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Prevail Partners is a Philadelphia-based private life sciences investment fund that takes equity stakes in companies running Phase I-IV clinical trials, using proprietary benchmarking analytics and turnkey Build-to-Suit infrastructure from its affiliate Prevail InfoWorks to de-risk trials and accelerate value monetization.

Ownership category

akta.pro rank

Product category

Life Sciences Investment Fund

NAICS

Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

akta.pro secondary industries

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Clinical Trial Financial Management & Payments (Site Budgeting) (HLAGACAM)

Keywords

• Life sciences investment
• Venture capital
• Clinical trial funding
• Healthcare investment
• Biotech funding

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Investment Returns and Capital Gains: Prevail Partners generates returns through equity investments in life sciences companies. The fund realizes value through successful clinical studies and timely monetization via licensing and commercialization. Returns are achieved when invested companies reach clinical milestones or successful exits.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Prevail Partners operates the Health Value Fund, a private investment vehicle that provides equity capital to life sciences companies sponsoring Phase I–IV clinical trials. The fund applies proprietary patented benchmarking and analytics from affiliate Prevail InfoWorks, Inc. to evaluate investment targets, de-risk clinical development, and monetize assets through licensing and commercialization. Its Build-to-Suit program offers project financing, flexible turnkey clinical services, and a collaboration platform for engaging strategic partners during trials.

Product overview

Prevail Partners operates as a life sciences investment fund offering a single unified investment platform. The core offering is the Health Value Fund, which provides capital and proprietary clinical development intelligence to life sciences companies. The fund leverages affiliate Prevail InfoWorks' patented benchmarking libraries and analytics platform for investment evaluation, and offers the Build-to-Suit Program for comprehensive clinical development services. Key proprietary technologies include the Patented Benchmarking Libraries and Analytics Platform for trial metrics comparison, the Projected Outcome Analysis (POA) tool for real-time study performance monitoring, and the Patented Collaboration Platform for stakeholder engagement during clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Health Value Fund
• Build-to-Suit Program

Quantifiable outcome

• United Therapeutics market value jumped approximately $300 million based on TRIUMPH-1 trial results using Prevail's system
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Omnix MedicalcoreStrategic or Co-development Partner · 6 November 2025Strategic and financial partnership aimed at advancing Omnix Medical's pipeline of anti-infective drugs, including the Phase 2 trial of OMN6 for resistant bacterial infections. Prevail Partners invested in Omnix Medical and provides clinical trial services through its affiliate Prevail InfoWorks to support development and potential regulatory approval of OMN6.
• Prevail InfoWorks Inc.coreStrategic or Co-development PartnerAffiliate portfolio company of Prevail Partners providing proprietary technologies for clinical trial design, oversight, and outcomes management. Their patented technologies applied to every phase of trials give Prevail Partners' investments an unmatched level of intelligence and control for product development. The selection process is made possible by expertise lodged in Prevail InfoWorks.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Deerfield Management: Healthcare-focused investment firm that combines traditional venture capital, public equities, and credit with operational support services. Comparable as an integrated healthcare investment platform serving life sciences companies.
• Frazier Healthcare Partners: Healthcare-dedicated investment firm investing across biopharma and medical devices. Comparable to Prevail as a focused healthcare PE/VC with both growth and clinical-stage investment strategies.
• OrbiMed Advisors: One of the largest healthcare-dedicated investment firms globally, investing across biopharmaceuticals, medical devices, and diagnostics. Directly comparable to Prevail as a life sciences-focused investment firm, though at vastly larger scale.
• Medicxi: Life sciences-only investment firm with a focus on late-stage clinical assets and asset-centric structures. Closely comparable to Prevail's Build-to-Suit model of advancing individual clinical assets in dedicated structures.
• Longitude Capital: Healthcare-focused investment firm that invests in both private and public companies developing medical technologies. Comparable to Prevail as a healthcare-dedicated growth investor supporting clinical-stage companies.
• RA Capital Management: Healthcare-focused investment manager combining public and private life sciences investing with deep scientific diligence. Comparable to Prevail's model of integrating rigorous clinical/regulatory analysis with capital deployment in clinical-stage assets.
• Atlas Venture: Early-stage life sciences venture firm that builds and invests in biotech companies. Comparable to Prevail as a specialist life sciences investor focused on clinical translation and value-inflection events.
• Pappas Capital: Life sciences and technology venture firm focused on early- to mid-stage biotech, specialty pharma, and medical devices. Comparable to Prevail as a North Carolina-based life sciences specialist, though with broader therapeutic scope.
• Sanderling Ventures: One of the oldest continuously operating venture firms dedicated to building new life sciences companies from early-stage research. Comparable to Prevail as a long-tenured, life sciences-specialized investment firm.

Broad incumbents

• New Enterprise Associates (NEA): Large, multi-stage venture capital firm with a dedicated healthcare practice. Comparable to Prevail in the life sciences investing overlap, but operates at much larger scale and with broader technology and healthcare diversification.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/prevail-partners-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prevail Partners